Comunicato stampa commerciale
GEA opens a new chapter for biopharmaceutical separation processes with pharma separator lines aseptic and pure
06 Jul 2021
With the introduction of the new separator lines aseptic and pure under the motto "Energizing Pharma", pharmaceutical specialist GEA is ushering in a new era for biopharmaceutical separation processes.
GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)
Based on GEA's decades of expertise in the field of mechanical separation technology, GEA engineers have developed a new, fully comprehensive portfolio of plug & produce pharma separator systems that moves harmoniously and perfectly between individual and process-related requirements and leaves nothing to be desired. The separator lines aseptic and pure are used in all pharmaceutical and biotechnological downstream processes. GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. The pure line is used in applications with varying hygienic requirements such as nutritional supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery.
Perfectly adapted separation solution from GEA
The biopharmaceutical industry is united by a common denominator. It places the highest value on uncompromising hygienic design, process reliability and high yield. However, the detailed requirements can vary widely depending on process regulations and specifications. GEA took this requirement profile as an opportunity to develop a separation solution for the biopharmaceutical industry that is perfectly adaptable in every respect.
Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)
Development to the highest GEA standards
The new pharmaceutical separator lines "aseptic" and "pure" were developed to the highest GEA standards at the German GEA Westfalia Separator plant in Oelde, where they are built and tested. The aseptic line stands for the highest hygienic pharmaceutical requirements. The pure line provides maximum variability and is perfectly tailored to the diverse process requirements of the biopharmaceutical industry. All functions for pharmaceutical cleanliness requirements such as an automatic CIP (Cleaning-in-Place), SIP (Steam Sterilization in Place), simple validation and a high-end qualification package are included. In addition, with the help of the cGMP validation process ("Current Good Manufacturing Practice, cGMP), the pharma separators support GEA customers in their quality standard reviews.
Contact
Dr. Michael Golek
Media Relations
GEA Group Aktiengesellschaft
Peter-Müller-Str. 12
40468
Düsseldorf
Germany
+49 211 9136-0
Informazioni su GEA
GEA è fra i principali fornitori dell'industria di processo alimentare e di una vasta gamma di altri settori. Nel 2019 ha realizzato un fatturato consolidato di circa 4,9 miliardi di euro.
